Emerging biologics in severe asthma

Emerging biologics in severe asthma

Detalhes bibliográficos
Principais autores:	Pavord, I, Hilvering, B, Shrimanker, R
Formato:	Journal article
Publicado em:	Elsevier 2016

Registros relacionados

Interleukin-5 inhibitors for severe asthma: Rationale and future outlook.
por: Shrimanker, R, et al.
Publicado em: (2017)

Evidence for the efficacy and safety of anti- interleukin-5 treatment in the management of refractory eosinophilic asthma
por: Xue, L, et al.
Publicado em: (2015)

Management and mechanisms of severe eosinophilic asthma
por: Shrimanker, R
Publicado em: (2020)

Exacerbations of severe asthma in patients treated with mepolizumab
por: Shrimanker, R, et al.
Publicado em: (2018)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
por: Howell, I, et al.
Publicado em: (2024)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
por: Shrimanker, R, et al.
Publicado em: (2018)

Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide and their combination in severe asthma: a post-hoc analysis
por: Shrimanker, R, et al.
Publicado em: (2019)

Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma
por: Bart Hilvering, et al.
Publicado em: (2015-08-01)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
por: Shrimanker, R, et al.
Publicado em: (2017)

Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma
por: Trivedi, A, et al.
Publicado em: (2016)

Biological therapies for asthma
por: Couillard Castonguay, S, et al.
Publicado em: (2021)

The effect of oral corticosteroids on circulating type-2 cytokine producing cells in patients with severe eosinophilic asthma
por: Hynes, G, et al.
Publicado em: (2018)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
por: Shrimanker, R, et al.
Publicado em: (2017)

FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma
por: Couillard, S, et al.
Publicado em: (2021)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
por: Imran Howell, et al.
Publicado em: (2024-07-01)

Mechanisms of FeNO non-suppression in severe asthma: analysis of sputum type 2 cytokines and chemokines
por: Couillard, S, et al.
Publicado em: (2020)

Inhibition of asthma-related immunological responses in mast cells and Th2 cell lines by cultured epithelial cell lines
por: Powell, T, et al.
Publicado em: (2016)

Inhibition of asthma relevant innate and adaptive human immune cells by epithelial cells
por: Powell, T, et al.
Publicado em: (2016)

IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma
por: Luo, J, et al.
Publicado em: (2024)

Mepolizumab, quality of life, and severe eosinophilic asthma.
por: Pavord, I
Publicado em: (2017)

Type-2 CD8+ T lymphocytes responsive to PGD2/LTE4 in severe eosinophilic asthma
por: Hinks, T, et al.
Publicado em: (2018)

FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma
por: Couillard, S, et al.
Publicado em: (2021)

Severe T2-high asthma in the biologics era: European experts' opinion
por: Pavord, I, et al.
Publicado em: (2019)

Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma
por: Hilvering, B, et al.
Publicado em: (2018)

Will precision medicine become an effective tool for airway disease?
por: Shrimanker, R, et al.
Publicado em: (2018)

Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma
por: Berair, R, et al.
Publicado em: (2013)

Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma.
por: Berair, R, et al.
Publicado em: (2013)

Severe T2-high asthma in the biologics era: European experts' opinion
por: Ian Pavord, et al.
Publicado em: (2019-07-01)

Diagnosing eosinophilic asthma using a multivariate prediction model based on blood granulocyte responsiveness.
por: Hilvering, B, et al.
Publicado em: (2016)

Biomarkers for severe eosinophilic asthma.
por: Yancey, S, et al.
Publicado em: (2017)

Biological therapy of severe bronchial asthma
por: I. Melnychaiko, et al.
Publicado em: (2023-06-01)

Is the neutrophil the key effector cell in severe asthma?
por: Kamath, A, et al.
Publicado em: (2005)

Biological therapy for severe asthma
por: Silvano Dragonieri, et al.
Publicado em: (2021-08-01)

Biological treatments for severe asthma
por: Hyun Jung Jin
Publicado em: (2020-10-01)

A novel CT scoring system differentiates admissions secondary to eosinophilic from non-eosinophilic asthma
por: Hynes, G, et al.
Publicado em: (2017)

Emerging therapies for severe asthma
por: Spears Mark, et al.
Publicado em: (2011-09-01)

Sputum Il-17a levels correlate with biomarkers of non-eosinophilic inflammation in patients with asthma
por: Hynes, G, et al.
Publicado em: (2017)

How I do it: workup of severe asthma
por: Couillard, S, et al.
Publicado em: (2021)

A new approach to the classification and management of airways diseases: identification of treatable traits
por: Shrimanker, R, et al.
Publicado em: (2017)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
por: Yancey, S, et al.
Publicado em: (2016)